Use of simeprevir following pre‐emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12‐week pilot study

Publisher： John Wiley & Sons Inc

E-ISSN： 1868-6982|22|2|144-150

ISSN： 1868-6974

Source： JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol.22, Iss.2, 2015-02, pp. : 144-150

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation

By  

HEPATOLOGY RESEARCH, Vol. 46, Iss. 11, 2016-10 ,pp. : 1118-1128

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 11, 2015-11 ,pp. : 2442-2447

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus–coinfected liver transplant recipients

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 2, 2015-02 ,pp. : 272-274

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 6, 2015-06 ,pp. : 823-830

John Wiley & Sons Inc

Access to resources Recommend Favorite

Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E146-E154

John Wiley & Sons Inc

Access to resources Recommend Favorite